Muramyl dipeptide and its derivatives: peptide adjuvant in immunological disorders and cancer therapy

Chikako Ogawa1, Yuen-Joyce Liu, Koichi S Kobayashi

  • 1Eisai Research Institute, 4 Corporate drive, Andover, MA 01810.

Current Bioactive Compounds
|December 20, 2011
PubMed

Insights

Muramyl dipeptide (MDP), a bacterial cell wall component, activates the innate immune system via NOD2. Structural modifications of MDP aim to enhance immune responses for treating cancer and autoimmune diseases.

Area of Science:

  • Immunology
  • Medicinal Chemistry
  • Molecular Biology

Background:

  • Muramyl dipeptide (MDP) is a key component of bacterial peptidoglycan.
  • MDP is recognized by NOD2, a cytoplasmic receptor of the innate immune system.
  • NOD2 pathway activation is implicated in autoimmune diseases like Crohn's disease.

Purpose of the Study:

  • To review the synthetic chemistry of MDP and its derivatives.
  • To discuss the pharmacological actions of MDP and its analogs.
  • To explore stereoselective synthesis methods for MDP derivatives.

Main Methods:

  • Literature review of synthetic chemistry approaches.
  • Analysis of pharmacological data on MDP and derivatives.
  • Examination of stereoselective synthesis strategies.

Main Results:

  • MDP's structure and its role in innate immunity are detailed.
  • The significance of the MDP-NOD2 interaction in immunity and disease is highlighted.
  • Various synthetic modifications of MDP are presented.

Conclusions:

  • MDP and its derivatives hold potential as immunoadjuvants.
  • Further research into structural modifications can optimize immune responses.
  • Targeting the MDP-NOD2 pathway offers therapeutic possibilities for cancer and autoimmune disorders.